title: [Utility of platelet-rich plasma and growth factors bone in the bone defects. Regional Hospital Lic. Adolfo López Mateos, ISSSTE].
abstract: BACKGROUND
  The platelet-rich plasma is a concentrated of platelets with the presence of growth factors and proteins that serve as osteoconducer matrix for bone formation. We present the results obtained with the use of platelet-rich plasma and a hydroxyapatite and bovine collagen graft in the management of bone defects.
  
  
  METHODS
  We studied eight patients with bone defects, treated surgically in whom platelet rich plasma and a hydroxyapatite and bovine collagen graft was used, with clinical and radiographic follow-up at 2, 4, 6, 10 and 18 weeks after surgery.
  
  
  RESULTS
  Starting on week 7 since surgery, evidence of osteointegration and bone callus formation, during the weeks 10 and 14 most cases showed bone consolidation. A case without consolidation through week 18.
  
  
  CONCLUSIONS
  The immediate response of the body tissue damaged is the accumulation of a large number of activated platelets, which release their granules and growth factors that promote the regeneration of tissues. It is possible to obtain platelet-rich plasma and accelerating the process of bone regeneration. Our study shows beneficial results with the use of platelet-rich plasma.
authors.affiliation: Hospital Regional Lic. Adolfo López Mateos ISSSTE, México, D.F.
authors.forename: Trinidad Ramón Mendieta
authors.initials: TR
authors.lastname: Archundia
authors.forename: Juan Carlos Alvarado
authors.initials: JC
authors.lastname: Soriano
authors.forename: Jorge Negrete
authors.initials: JN
authors.lastname: Corona
mesh_terms: D000077:Acetabulum / Q000601:surgery*; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000601:surgery; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001792:Blood Platelets / Q000378:metabolism; D018786:Bone Substitutes / Q000008:administration & dosage / Q000627:therapeutic use*; D002417:Cattle; D003094:Collagen / Q000008:administration & dosage / Q000627:therapeutic use*; D017886:Durapatite / Q000008:administration & dosage / Q000627:therapeutic use*; D005109:Extracellular Matrix; D005260:Female; D005269:Femur / Q000601:surgery*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016348:Osseointegration; D010020:Osteonecrosis / Q000601:surgery; D053657:Platelet-Rich Plasma; D011183:Postoperative Complications / Q000601:surgery; D011446:Prospective Studies; D011542:Pseudarthrosis / Q000601:surgery; D013977:Tibia / Q000601:surgery*
chemical_list: D018786:Bone Substitutes; D036341:Intercellular Signaling Peptides and Proteins; D003094:Collagen; D017886:Durapatite